Literature DB >> 11998908

Cerebrospinal fluid levels of cytokines and soluble tumour necrosis factor receptor in acute disseminated encephalomyelitis.

Takashi Ichiyama1, Hiroshi Shoji, Mitsuhiro Kato, Yukio Sawaishi, Hiroshi Ozawa, Tomoyo Matsubara, Susumu Furukawa.   

Abstract

UNLABELLED: We determined the concentrations of interleukin-1beta (IL-1beta, IL-6, IL-10, interferon-gamma (IFN-gamma), tumour necrosis factor-alpha (TNF-alpha), and soluble TNF receptor 1 (sTNFR1) in CSF from 18 patients with acute disseminated encephalomyelitis (ADEM) to investigate the role of cytokines in the pathogenesis of the disease in the acute stage. Cytokines and sTNFR1 were measured by ELISA. The CSF IL-6, IL-10, TNF-alpha, and sTNFR1 concentrations were elevated in 16, 13, 3, and 11 of the 18 patients with ADEM, respectively. CSF concentrations of IL-10 and sTNFRI correlated positively with each other in the patients (P<0.01). Myelin basic protein levels in CSF of the patients with elevated CSF sTNFR1 levels were significantly higher than those in CSF of the patients with normal CSF sTNFR1 levels (P<0.05). IL-1beta and IFN-gamma were not elevated in CSF. Our results suggest that IL-6 and TNF-alpha mediate inflammation in the central nervous systems in ADEM. We speculated that TNF-alpha is related to demyelination and that IL-10 is induced to modulate TNF-alpha-induced inflammation in ADEM.
CONCLUSION: these findings suggest that cytokines such as tumour necrosis factor-alpha, soluble tumour necrosis factor receptor 1, interleukin-6, and interleukin-10 are related to the pathogenesis of acute disseminated encephalomyelitis in the acute stage.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11998908     DOI: 10.1007/s00431-001-0888-2

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  9 in total

Review 1.  SARS-CoV-2 and nervous system: From pathogenesis to clinical manifestation.

Authors:  Kiandokht Keyhanian; Raffaella Pizzolato Umeton; Babak Mohit; Vahid Davoudi; Fatemeh Hajighasemi; Mehdi Ghasemi
Journal:  J Neuroimmunol       Date:  2020-11-07       Impact factor: 3.478

2.  Serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in non-herpetic acute limbic encephalitis.

Authors:  Takashi Ichiyama; Yukitoshi Takahashi; Takeshi Matsushige; Madoka Kajimoto; Shinnosuke Fukunaga; Susumu Furukawa
Journal:  J Neurol       Date:  2009-08-12       Impact factor: 4.849

Review 3.  Expanding Role of T Cells in Human Autoimmune Diseases of the Central Nervous System.

Authors:  Deepti Pilli; Alicia Zou; Fiona Tea; Russell C Dale; Fabienne Brilot
Journal:  Front Immunol       Date:  2017-06-07       Impact factor: 7.561

Review 4.  Pregnancy-Related Immune Changes and Demyelinating Diseases of the Central Nervous System.

Authors:  Ke Qiu; Qiang He; Xiqian Chen; Hui Liu; Shuwen Deng; Wei Lu
Journal:  Front Neurol       Date:  2019-10-09       Impact factor: 4.003

5.  Cytokines and chemokines profile in encephalitis patients: A meta-analysis.

Authors:  Alireza Soltani Khaboushan; Mohammad-Taha Pahlevan-Fallahy; Parnian Shobeiri; Antônio L Teixeira; Nima Rezaei
Journal:  PLoS One       Date:  2022-09-01       Impact factor: 3.752

Review 6.  Postinfectious encephalomyelitis.

Authors:  Dean M Wingerchuk
Journal:  Curr Neurol Neurosci Rep       Date:  2003-05       Impact factor: 6.030

Review 7.  Acute disseminated encephalomyelitis.

Authors:  Adil Javed; Omar Khan
Journal:  Handb Clin Neurol       Date:  2014

Review 8.  The magnetic resonance imaging appearance of monophasic acute disseminated encephalomyelitis: an update post application of the 2007 consensus criteria.

Authors:  Samantha E Marin; David J A Callen
Journal:  Neuroimaging Clin N Am       Date:  2013-02-26       Impact factor: 2.264

9.  Acute disseminated encephalomyelitis associated with hepatitis B virus reinfection--consequence or coincidence?

Authors:  Ines Lazibat; Vesna Brinar
Journal:  Clin Neurol Neurosurg       Date:  2013-12       Impact factor: 1.876

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.